Compositions and methods for the therapy and diagnosis of cytomegalovirus
The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
1. An isolated anti-CMV antibody, wherein said antibody comprises:
(a) a V H region comprising
(i) a V H CDR1 region comprising the amino acid sequence of SSNGIH (SEQ ID NO: 57);
(ii) a V H CDR2 region comprising the amino acid sequence of VISSDANDKQYADSVKG (SEQ ID NO: 58); and
(iii) a V H CDR3 region comprising the amino acid sequence of DGTCSGGNCYSGLIDY (SEQ ID NO: 59); and
(b) a V L region comprising
(i) a V L CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);
(ii) a V L CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO: 64); and
(iii) a V L CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO: 65).
2. An isolated anti-CMV antibody, wherein said antibody comprises:
(a) a V H region comprising
(i) a V H CDR1 region comprising the amino acid sequence of GFTFSS (SEQ ID NO: 60);
(ii) a V H CDR2 region comprising the amino acid sequence of VISSDANDKQ (SEQ ID NO: 61); and
(iii) a V H CDR3 region comprising the amino acid sequence of DGTCSGGNCYSGLIDY (SEQ ID NO: 59); and
(b) a V L region comprising
(i) a V L CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);
(ii) a V L CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO: 64); and
(iii) a V L CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO: 65).
3. An isolated anti-CMV antibody comprising:
a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 56 and a light chain sequence comprising amino acid sequence SEQ ID NO: 63.
4. The anti-CMV antibody of claim 1 , wherein said antibody binds an epitope of the glycoprotein b (gB) envelope protein of the CMV virus.
5. The anti-CMV antibody of claim 4 , wherein said epitope comprises the antigenic determinant 2 site 1 of gB, gp116.
6. A composition comprising the antibody of claim 1 .
7. The composition of claim 6 , further comprising an anti-viral treatment.
8. The composition of claim 7 , wherein said anti-viral treatment is ganciclovir, foscarnet, cidofovir, valganciclovir, and intravenous immunoglobulin (IVIG).
9. The composition of claim 6 , further comprising a second anti-CMV antibody.
10. The antibody of claim 1 , wherein said antibody is operably-linked to a therapeutic agent or a detectable label.
11. A diagnostic kit comprising the antibody according to claim 1 .